White Paper
Chromogenic Multiplex IHC Assay
Key topics discussed:
- Why choose chromogenic multiplex immunohistochemistry?
- Steps to follow to develop mIHC assays
- Our CD8/Granzyme B (GZMB)/FOXP3 assay and its clinical applications
- Challenges and future developments in the field
Why Choose CellCarta for your Histopathology Assays
We perform tissue analysis for biomarkers, clinical testing, and companion diagnostics using cutting-edge technologies and capabilities such as multiplex IHC and RareCyte. By supporting our team of in-house pathologists with AI we transform tissue biology into actionable data.
Contact us